--- title: "Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG" type: "News" locale: "en" url: "https://longbridge.com/en/news/282177167.md" description: "Shanghai Henlius Biotech, Inc. has received Chinese regulatory approval to expand the indications for its rituximab biosimilar, HANLIKANG. The approval allows for two new combination therapies for adult patients with untreated and relapsed or refractory diffuse large B-cell lymphoma. This expansion enhances Henlius's oncology portfolio in a market valued at approximately RMB3.465 billion, providing more treatment options for patients. The stock is currently rated as a Buy with a price target of HK$99.78, reflecting positive market sentiment." datetime: "2026-04-09T10:12:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282177167.md) - [en](https://longbridge.com/en/news/282177167.md) - [zh-HK](https://longbridge.com/zh-HK/news/282177167.md) --- # Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG ### Easter Sale - 70% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update. Shanghai Henlius Biotech has secured Chinese regulatory approval to expand the indications of its rituximab biosimilar HANLIKANG, adding two combination therapies for adult patients with previously untreated and relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem cell transplantation. The decision broadens HANLIKANG’s clinical use across non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis, strengthening the company’s oncology franchise in a domestic rituximab market worth about RMB3.465 billion and offering more treatment options for lymphoma patients in China. HANLIKANG, already approved in the Chinese Mainland as well as in Nicaragua and Bolivia, can now be combined with polatuzumab vedotin plus chemotherapy in first-line DLBCL and with bendamustine and polatuzumab vedotin in difficult-to-treat relapsed or refractory cases. The expanded label is expected to enhance Henlius’s competitive position in China’s biologics market by leveraging a broader indication spectrum and potentially capturing greater share of the sizeable rituximab segment, benefiting both the company and its stakeholders through increased commercial opportunities and expanded patient access. The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page. **More about Shanghai Henlius Biotech, Inc. Class H** Shanghai Henlius Biotech, Inc. is a Chinese biopharmaceutical company focused on developing and commercializing therapeutic biological products, including biosimilars such as rituximab. Its flagship rituximab biosimilar, marketed as HANLIKANG, targets oncology and autoimmune indications in the Chinese Mainland and select international markets. **Average Trading Volume:** 1,147,828 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$43.07B ### Related Stocks - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [02696.HK](https://longbridge.com/en/quote/02696.HK.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) ## Related News & Research - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [FDA approves FoundationOne CDx as TEPMETKO companion diagnostic in NSCLC](https://longbridge.com/en/news/287246470.md) - [Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial](https://longbridge.com/en/news/286246864.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)